The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.
Nanoparticle therapeutics: an emerging treatment modality for cancer
Abstract
Nanoparticles--particles in the size range 1-100 nm--are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using cell membranes and EVs as carriers in nanomedicine offers significant advantages, including exceptional biological compatibility, biodegradability, and a superior drug-loading performance.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [189]
In the citing paper
“Additionally, nanopharmaceuticals derived from cell membranes and their byproducts naturally contain targeting ability, making them especially promising for the research and development of drug transport systems in lymphoma treatment.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [189]
In the citing paper
“Immobilization of an enzyme on the surface of nanoparticles can increase enzyme stability (31), and we therefore developed DNase I-coated nanoparticles.”
From Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps (2016) · cites this paper as [31]
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,978
Self-citationMechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201
Self-citationGradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc903 · Cited by 1,648
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,129
Flagged first, then by citations
2 of the 108 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Kurtzberg, J., Moore, J. O. Scudiery, D. & Franklin, A. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. Am. Assoc. Cancer Res. 29, 213 (1988).
- Socinski, M. & Ramalingham, S. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological differences between men and women: is gender-specific therapy warranted? Chemotherapy Foundation web site [online], (2005).
- Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug–polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999).
Cited by
Sorted by citations
Metal–Organic Frameworks in Biomedicine
Horcajada, P., Gref, R., Baâti, T., Allan, P. K., Maurin, G., Couvreur, P., Férey, G., Morris, R. E., & Serre, C. (2011) · Chemical Reviews · doi:10.1021/cr200256v · Cited by 4,241
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,265
Nanoparticles in Photodynamic Therapy
Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,999
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,898
Metadata
- Authors
- Davis, M. E., Chen, Z., & Shin, D. M.
- Affiliations
- California Institute of Technology (US)
- Emory University (US)
- Corresponding author
- Davis, Mark E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-09
- Volume
- 7
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2082511916
- Cited by
- 4,233
- References
- 108
- Citations by year
- 2026: 68 · 2025: 134 · 2024: 165 · 2023: 143 · 2022: 171 · 2021: 217 · 2020: 224 · 2019: 260 · 2018: 316 · 2017: 340 · 2016: 364 · 2015: 383 · 2014: 385 · 2013: 332 · 2012: 268
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- National Cancer Institute (U54CA119338)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- nanotherapeutics, cancer therapy, nanomedicine, targeted drug delivery, tumor localization, cellular uptake, clinical translation, clinical trials, anticancer agents, adverse drug reactions
- MeSH terms
- Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
